In recent years an increase of functional CD4 + CD25 + regulatory T cells (T reg cells) has been established for patients with solid tumors, acute leukemias, and lymphomas. We have reported an expanded pool of CD4 + CD25 high T reg cells in patients with chronic lymphatic leukemia (CLL), multiple myeloma (MM) as well as its premalignant precursor monoclonal gammopathy of undetermined significance (MGUS). In healthy individuals, low-level expression of CD127 on T cells in addition to the expression of FOXP3 has been associated with T reg cells. Here, we demonstrate that the expanded FOXP3 + T-cell population in patients with colorectal cancer, CLL, MGUS, MM, follicular lymphoma, and Hodgkin's disease are exclusively CD127 low T reg cells and were strongly suppressive. A significant portion of CD127 low FOXP3 + T reg cells expressed only low levels of CD25 suggesting that the previously reported expansion of CD25 + T reg cells underestimates the true expansion. The assessment of CCR7 and CD45RA expression on the expanded CD4 + CD127 low FOXP3 + T reg cells revealed an increase of both naïve as well as central and effector memory T reg cells in peripheral blood. Our data strongly support superiority of combined CD127 and FOXP3 analysis in comparison to CD25 and FOXP3 assessment for further quantification of T reg cells in malignant diseases.
Introduction
CD4 + CD25 + regulatory T cells (T reg cells) are expanded in murine tumor models, and their deletion can lead to complete tumor regression [1] . In humans, T reg cells are mostly enriched in the CD4 + CD25 high T-cell population [2] . We and others have reported increased frequencies of CD4 + CD25 high FOXP3 + T reg cells in cancer patients [1, 3] . However, the expansion of T reg cells based on the assessment of CD25 is likely to underestimate the true expansion since FOXP3 + T cells are also present in the CD25 −/low fraction [4, 5] . Furthermore, molecular and functional characterization of this population is hampered by the inability to separate CD25 + T reg cells from activated effector T cells. Two recent studies, however, have shown that reciprocal expression of the IL7 receptor (CD127) on FOXP3 + T reg cells is most likely a more specific way to quantify FOXP3 + T reg cells [5, 6] . This has been adopted lately for the quantification of T reg cells in solid tumors [7] [8] [9] [10] and hematologic malignancies [11] [12] [13] , with one of the reports establishing CD127 as an even superior marker for the identification of T reg cells in cancer patients [9] . However, no systematic analysis has been undertaken to establish CD127 as a superior marker for T reg -cell enumeration in cancer patients, and only one initial report of malignant melanoma patients has addressed reciprocal expression of CD127 and FOXP3 on T reg cells in cancer patients independently of CD25 [9] . It is, therefore, necessary to determine whether CD127 is also a better marker for enumerating FOXP3 + T reg cells in cancer patients in general by comparing T reg cells numbers in a larger number of different tumor subtypes. Besides the integration of CD25 low/− FOXP3-expressing T reg cells, analysis of CD127 might, furthermore, clarify contradictory results concerning frequencies as well as prognostic value of T reg cells in cancer patients [14] [15] [16] .
Similarly, there is still debate whether human CD4 + CD25 high FOXP3 + T reg solely belong to the memory T-cell compartment [17] . Valmori et al. were the first to identify a T reg -cell population with a naïve phenotype (CCR7 + CD45RA + ), which they termed natural naïve T reg cells [18] . As expected, the frequency of these naïve T reg cells was relatively low in healthy individuals [19] . More recently, Seddiki et al. have described the persistence of a population of naïve CD45RA + T reg cells in adult life [20] , which was further characterized by resistance to CD95L-induced cell death [21] . Recent data further supports that a population of naïve T reg cells exist in healthy individuals that exerts suppressive function [22] . So far, our own observations suggested an increased frequency of naïve CD4 + CD25 high FOXP3 + T reg cells in MM and MGUS [23] . However, previous findings were restricted to the CD4 + CD25 high subpopulation excluding a significant fraction of T reg cells from analysis. With the emergence of CD127 as a new marker separating T reg cells from conventional T cells, the question whether the expanded T reg cells in cancer patients are mainly antigenexperienced memory cells or also naïve T reg cells needs reevaluation.
Here, we present clear evidence that FOXP3 + T cells derived from patients with CLL, MGUS, MM, follicular lymphoma (FL), Hodgkin's disease (HD), and colorectal cancer (CRC) are lacking CD127. This newly defined fully functional CD4 + CD127 low FOXP3 + T reg -cell population is expanded in all tumor entities as well as the premalignant MGUS supporting the hypothesis of increased T reg cells as a rather early event during tumor development. Moreover, we demonstrate a significant increase of naïve CD4 + CD127 low FOXP3 + T reg cells in peripheral blood of cancer patients while we could not detect an increase in lymph node biopsies of lymphoma patients. Finally, these data strongly support the assessment of CD127 expressioninstead of CD25-in combination with FOXP3 for a more precise enumeration of T reg cells in malignant diseases while functional characterization still relies on the combination of CD127 and CD25.
Material and Methods

Patients and Clinical Parameters.
Following approval by the institutional review board of the University of Cologne, peripheral blood from 10 healthy individuals, 7 MGUS, 10 MM, 10 CLL and 6 patients with CRC (2 time points at least 1 month apart) was obtained after informed consent. For the assessment of T reg cell numbers in lymph node biopsies, lymph nodes from 7 healthy donors, 6 patients with HD, and 7 patients with FL were analyzed following approval by the institutional review board of the University of Cologne. Patients were either untreated or had not received cytoreductive treatment for a period of at least 1 month prior to investigation. Characteristics of the patients studied are summarized in Tables 1 and 2 . Phenotype of T cells was  defined by flow cytometry using the following antibodies:  CD45RA-PE-Cy5 (HI100), CD127-PE (hIL-7R-M21), CD4-APC-Cy7 (RPA-T4), CD25-PE-Cy7 (M-A251, all from Becton Dickinson), CCR7-FITC (150503, R&D) To assess the suppressive activity of CD4 + CD127 low CD25 +/low T cells, a modified MLR was performed as previously described [23] . Briefly, CD4 + CD127 low CD25 +/low and CD4 + CD127 + CD25 − T cells were stained with CD4, CD25, and CD127 mAb and sorted on a FACSDiVa or FACS Aria III (both BD Biosciences) and incubated for 20 hours with 10 U/mL IL-2 (Proleukin) and 0.5 μg/mL anti-CD3 (OKT3) in X-VIVO 15 (BioWhittakker) [24] . Subsequently, CD4 + CD127 + CD25 − T cells were stained with 5,6-Carboxyfluorescin-DiacetatSuccinimidyl-Ester (CFSE, Sigma-Aldrich) and stimulated in X-VIVO 15 supplemented with 10% fetal calf serum, 100 U/mL penicillin/streptomycin and 2 mM glutamine (Invitrogen) with magnetic beads (Dynal Biotech,) coated with 5% anti-CD3, 14% anti-CD28 (9.3), and 81% anti-MHC class I (W6/32) at a ratio of 3 : 1 (cells : beads). To assess inhibitory capacity of T reg cells from cancer patients, autologous CD4 + CD127 low CD25 +/low T reg cells were added at a 1 : 1 ratio to the culture, and the proliferation of CD4 + CD127 + CD25 − T cells was determined by assessing CFSE dilution after four days of culture as described previously [23] .
Antibodies and FACS Analysis.
RNA Preparation and Quantitative Real-Time PCR.
For analysis of CD127 mRNA expression, CD4 + CD25 − and CD4 + CD25 high T cells from five healthy donors and five CLL patients were purified as previously described [24] . The described technique is optimized for the isolation of human CD4 + CD25 high T cells with high purity [23, 24] . Cells were reanalyzed after sorting and routinely showed >95% purity. Subsequently, the cells were lysed in TRIzol reagent (Invitrogen). 50-100 ng RNA were reverse transcribed using the Transcriptor First Strand cDNA Synthesis Kit (Roche, Penzberg, Germany). Rt-PCR was performed with the LightCyclerTaqman master kit and Universal ProbeLibrary Assay on a Light Cycler 480 II. Analysis was performed using Light-Cycler3 and RelQuant software using a calibrator normalized relative quantification based on β-2 microglobulin (B2M) expression. Primers used: CD127 forward, 5 -AAAGTTTTAATGCACGATGTAGCTT-3 ; CD127 reverse, 5 -TGTGCTGGATAAATTCACATGC-3 ; Probe 72; B2M forward, 5 -TTCTGGCCTGGAGGCTAT-3 ; B2M reverse, 5 TCAGGAAATTTGACTTTCCATTC-3 ; Probe 42. 
Statistical Analysis.
Comparison between paired or unpaired groups was performed using the appropriate Student's t-test. A P-value < 0.05 was defined as statistically significant. Due to the explorative nature of this study, no multiplicity adjustment procedures were performed. All statistical analyses were performed using the SPSS statistical software package (SPSS 19.0, SPSS Inc.).
Results
Downregulation of CD127 mRNA Expression in CD4 +
CD25 high T reg Cells from CLL Patients. As CD25 is not solely expressed on T reg cells but also on activated conventional CD4 + T cells, and the downregulation of CD127 expression in CD4 + CD25 high FOXP3 + T reg cells from healthy donors has been reported [5, 6] , we first assessed if CD127 downregulation is also apparent in CD4 + CD25 high T reg cells from cancer patients. We detected a significant downregulation of CD127 mRNA expression in CD4 + CD25 high T cells from healthy donors (n = 5) as well as CLL patients (n = 5, P < 0.05, Figure 1(a) ) by quantitative PCR indicating that CD127 expression might also be used to specifically identify CD4 + FOXP3 + T reg cells in cancer patients. 
Coassessment of CD127 and FOXP3 for the Enumeration of
Human T reg Cells. Next the expression of CD127 in relation to FOXP3 and CD25 was evaluated by flow cytometry on CD4 + T cells. Gating on CD4 and CD25 with subsequent analysis of the CD4 + CD25 high T reg -cell population for expression of FOXP3 and CD127 confirmed the downregulation of CD127 in CD4 + CD25 high FOXP3 + T reg cells on protein level in healthy individuals (Figure 1(b) ). However, assessing coexpression of CD127 and FOXP3 by CD4 + T cells without gating beforehand on the CD4 + CD25 high T-cell population clearly revealed a significantly higher percentage of cells expressing FOXP3 but lacking CD127 (Figure 1(c) ). Subsequent analysis of the CD127 low FOXP3 + T reg -cell population for expression of CD25 demonstrated that gating on CD127 and FOXP3 identifies not only CD4 + CD25 high T reg cells but also T reg cells expressing only low levels of CD25 (Figure 1(c) ). The identification of this subpopulation of T reg cells is of specific interest as up to now only T reg cells expressing high amounts of CD25 were accessible to functional analysis. Figures 2(a) and 2(b) . In total, frequencies of T reg cells derived from peripheral blood of 12 patients with CRC, 10 CLL patients, 7 MGUS, and 10 MM patients as well as 10 healthy individuals were evaluated. In addition, lymph node biopsies from 7 patients with follicular lymphoma, 6 patients with Hodgkin's disease, and 7 reactive lymph nodes from healthy individuals were assessed for expanded T regcell numbers. Gating on CD4 and CD25 with subsequent gating on FOXP3 confirmed the already described increase of T reg cells in patients with CRC, CLL, MGUS, MM, FL, and HD (Figures 3(a) and 3(b) and Tables 3 and 4) . More important, when gating on FOXP3 and CD127 without using CD25 as primary inclusion criteria, frequencies of CD4 + CD127 low FOXP3 + T reg cells in controls (4.1% ± 0.7%) were similar to previously published results (Figure 3(c) and Table 3 ) [2, 5, 6, 24] . In contrast, individuals with CRC (7.2% ± 2.4%, P < 0.005), CLL (8.9% ± 4.0%, P < 0.005), as well as MM (11.7% ± 5.4%, P < 0.005) showed significantly increased frequencies of CD127 low FOXP3 + T reg cells compared to healthy individuals (Figure 3(c) and Table 3 ). Even in MGUS patients, a significantly higher frequency of T reg cells (6.0% ± 1.8%, P < 0.05) was observed (Figure 3(c) and Table 3 ), which is indicative of T reg -cell expansion as an early event in tumorigenesis. Similarly, we observed significantly increased frequencies of CD127 low FOXP3 + T reg cells in patients with FL (21.8% ± 8.0%, P < 0.01) and HD (24.4% ± 13.1%, P < 0.05) in comparison to reactive lymph node specimens from healthy individuals (10.1%±4.4, Figure 3(d) and Table 4 ). Moreover, the percentage of FOXP3 + cells within the CD4 + CD127 low T-cell population was always higher than within the CD4 + CD25 high population, suggesting that previous data only assessing a CD4 + CD25 high phenotype have underestimated the absolute increase of FOXP3 + T reg cells in cancer patients (Tables 3 and 4) . (Figure 4(b) ). To determine whether the CD4 + CD127 low CD25 +/low T reg cells from cancer patients are functional, we used an in vitro suppression assay. When activated with CD3/CD28 beads conventional CD4 + CD127 + CD25 − T cells, but not CD4 + CD127 low CD25 +/low T reg cells, proliferate strongly. In the presence of CD4 + CD127 low CD25 +/low T reg cells, this proliferation is suppressed (Figure 4(c)) . These data clearly demonstrate that CD4 + CD127 low CD25 +/low T cells are FOXP3 + and that these cells are fully functional in CRC patients. [18, 20, 25] . To determine which T reg -cell subpopulation is responsible for the increase of CD4 + CD127 low FOXP3 + T reg cells in cancer patients, we determined the frequency of naïve, central, and effector memory cells within the T reg -cell compartment from healthy individuals, CRC, CLL, MGUS, and MM patients ( Figure 5(a) ) and compared these data with those previously described for CD4 + CD25 high T reg cells in healthy individuals as well as MGUS and MM patients [18, 23] . In healthy individuals, naïve CCR7 + CD45RA + CD4 + CD127 low FOXP3 + T reg cells were hardly detectable (Figures 5(b) and 5(c) ). T reg cells were expanded population of central-memory T reg cells apparent in patients with FL and HD ( Figure 5(d) ). In addition, we could also detect an increase in effector-memory T reg cells ( Figure 5(d) ) while the pool of naïve T reg cells was basically absent independent if reactive or diseased lymph nodes were analyzed ( Figure 5(d) ).
Increase of CD4
Naïve CD4
Discussion
Expansion of CD4 + CD25 high T reg cells within the tumor microenvironment and peripheral blood has so far been accepted as a hallmark of cancer [1, 26, 27] . Moreover, augmented T reg -cell frequencies have been linked to tumor stage, prognosis, and survival [1, 26, 27] . We present new evidence that the increase of T reg cells in cancer was even underestimated previously due to suboptimal classification of T reg cells. Integrating analysis of FOXP3 with the cellsurface molecule CD127 clearly demonstrates that significantly higher numbers of CD127 low FOXP3 + T reg cells are expanded in cancer patients in general. The assessment of CD127 instead of CD25 is clearly superior in enumerating T reg cells in the diseased state. Natural T reg cells have been described as CD4 + CD25 + T cells in mice [28] , and initial reports in cancer patients relied solely on the assessment of CD4 and CD25 expression for the identification of T reg cells [3, 29] . Only since the identification of the transcription factor FOXP3 lineage-specific marker of T reg cells a more specific characterization of T reg cells is possible [28] . In murine models, FOXP3 expression is strongly associated with the CD25 + T reg -cell population. However, even the inclusion of FOXP3 assessment has been interpreted differentially when assessing frequencies of T reg cells in healthy individuals and cancer patients [23, 30] . The analysis of T reg cells in humans has been further complicated as several studies reported FOXP3 + cells within the CD4 + CD25 low or even CD4 + CD25
− population [5] , and even the reprogramming of T reg cells into effector T cells has been reported [31] . Therefore, a more specific definition of T reg cells based on unique or additional T regcell marker molecules is urgently needed. The introduction of CD127 as a new marker to distinguish T reg cells from conventional T cells is an important improvement and will help to clarify several previous conflicting results in human T reg -cell biology, particularly in cancer patients. Several recent studies have adopted the approach to use CD127, CD25, and FOXP3 for the quantification of T reg cells in tumor-bearing individuals and could demonstrate increased numbers of CD4 + CD25 high CD127 low T reg cells in patients with solid tumors [7] [8] [9] [10] and hematologic malignancies [11] [12] [13] . However, the majority of these reports focused solely on the enumeration of the T reg -cell compartment while at the same time focusing on only one tumor subtype. Only one study assessed T reg -cell numbers in more than one tumor subtype showing similar numbers of T reg cells for all gastrointestinal tumor subtypes analyzed [8] . Furthermore, these studies did not systematically compare possible marker combinations to establish the most suitable approach to identify T reg cells. This was analyzed in more detail in only one of the reports with the combination of CD127 and FOXP3 being the most appropriate combination to identify T reg cells in patients with malignant melanoma [9] .
The integration of CD127 permits to redefine the importance of CD25 expression on human T reg cells. Up to now, high expression of CD25 allowed for an enrichment of CD4 + T cells with regulatory properties [2] . However, it is undisputed that neither all human T reg cells are included by this approach nor that activated T cells expressing CD25 are excluded. Zelenay et al. could demonstrate a population of CD4 + CD25 − FOXP3 + T cells which can upregulate CD25 upon the depletion of all CD25 expressing cells and are able to replace the original T reg -cell population [4] . These data were a first hint that the expression of CD25 on T reg cells is similarly regulated like its expression on conventional T cells [4] . Human T reg cells need IL-2 for their survival and proliferation, and expression of the IL2R-α chain is certainly a prerequisite for IL-2 to exert its biological function [32] . However, the expression of CD25 is not homogenous and might also be dependent on the activation status and other exogenous factors [33] .
Using CD127 and FOXP3 to define human T reg cells demonstrates varying expression of CD25 in the CD4 + CD127 low FOXP3 + T reg -cell population. Additionally, the newly defined T reg -cell population comprises of significantly more T reg cells compared to the traditionally defined CD4 + CD25 high T reg cells as demonstrated recently for malignant melanoma [9] . Coassessment of CD127 and FOXP3 to determine T reg cells also resolves the uncertainty to differentiate between activated conventional T cells and T reg cells in patients with active disease. This is of particular importance when only using CD4 and CD25 for the identification of T reg cells in cancer patients, as contamination with effector T cells most frequently occurs when solely these two markers are used for analysis. As functional assessment of the CD4 + CD127 low FOXP3 + T reg -cell population is not possible as FOXP3 cannot be used for live studies of human T reg cells, using expression of CD4, CD25, and CD127 is the best possible approximation. T cells isolated by this approach almost exclusively express FOXP3. Moreover, when isolated from cancer patients, this T reg -cell population exerts strong inhibition.
Using a comparative approach analyzing different tumor subtypes from hematologic as well as epithelial origin, we demonstrate that all independent cancer patient groups studied uniformly show an expanded pool of CD4 + CD127 low FOXP3 + T reg cells. We therefore postulate that expansion of T reg cells is a general phenomenon in cancer patients. Moreover, since MGUS patients already have increased frequencies of T reg cells, it is very likely that expansion of T reg cells is an early event in the development of human tumors. Elevated T reg -cell levels might be associated with the progression from premalignant lesions that are still under control of the immune system to the uninhibited growth of malignant tumors.
The findings that naïve T reg cells are increased both in the premalignant state as well as in cancer patients might further support this hypothesis. T reg cells were first identified as antigen-experienced memory cells expressing CD45RO [2] . Only recently the existence of naïve T reg cells in human adults has been reported [18, 20, 22, 23, 34] , and the naïve T reg -cell population can be expanded in vitro while retaining its suppressive function [35, 36] . However, the physiological function of the naïve T reg -cell population remains unclear. Definition of T reg cells as CD4 + CD127 low FOXP3 + has enabled us to verify the increase of naïve T reg cells in MGUS and MM patients [23] and to extend these findings to CLL and CRC.
The identification of an expanded pool of naïve T reg cells in cancer patients opens new avenues to better understand the role of T reg cells in malignant disease. Memory T reg cells apparently cannot undergo self-renewal [37] . Therefore, the replenishment of an increased memory T reg -cell pool by differentiation of naïve T reg cells into memory T reg cells might be an alternative to the recently proposed conversion of conventional memory T cells to T reg cells [37] . In fact, the increased pool of naïve T reg cells with an unaltered frequency of memory T reg cells in premalignant MGUS suggests that expansion of naïve T reg cells is indeed preceding the expansion of memory T reg cells following differentiation during tumor development. Besides the expansion of naïve T reg cells through enhanced self-renewal and differentiation, other mechanisms have been proposed amongst them the interaction of CCR4 on T reg cells with CCL22 released in the tumor microenvironment [38] as well as the conversion of conventional CD4 + CD25
− T cells to T reg cells trough TGF-β [39] or prostaglandin E 2 [40] . How these factors influence the expansion of naïve T reg cells needs further clarification and might in the end result in better strategies to target expanded T reg cells in tumor patients.
In conclusion this study demonstrates that CD4 + CD127 low FOXP3 + T reg cells are increased in cancer patients. Definition of T reg cells by combining CD127 and FOXP3 has the advantage of including not only T reg cells expressing high levels of CD25 but also T reg cells with low CD25 expression and excluding at the same time activated conventional T cells. Furthermore, the naïve T reg -cell population is expanded in all tumor bearing individuals.
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